209 related articles for article (PubMed ID: 26251408)
1. Effects of metformin on metabolite profiles and LDL cholesterol in patients with type 2 diabetes.
Xu T; Brandmaier S; Messias AC; Herder C; Draisma HH; Demirkan A; Yu Z; Ried JS; Haller T; Heier M; Campillos M; Fobo G; Stark R; Holzapfel C; Adam J; Chi S; Rotter M; Panni T; Quante AS; He Y; Prehn C; Roemisch-Margl W; Kastenmüller G; Willemsen G; Pool R; Kasa K; van Dijk KW; Hankemeier T; Meisinger C; Thorand B; Ruepp A; Hrabé de Angelis M; Li Y; Wichmann HE; Stratmann B; Strauch K; Metspalu A; Gieger C; Suhre K; Adamski J; Illig T; Rathmann W; Roden M; Peters A; van Duijn CM; Boomsma DI; Meitinger T; Wang-Sattler R
Diabetes Care; 2015 Oct; 38(10):1858-67. PubMed ID: 26251408
[TBL] [Abstract][Full Text] [Related]
2. Metformin Effect on Nontargeted Metabolite Profiles in Patients With Type 2 Diabetes and in Multiple Murine Tissues.
Adam J; Brandmaier S; Leonhardt J; Scheerer MF; Mohney RP; Xu T; Bi J; Rotter M; Troll M; Chi S; Heier M; Herder C; Rathmann W; Giani G; Adamski J; Illig T; Strauch K; Li Y; Gieger C; Peters A; Suhre K; Ankerst D; Meitinger T; Hrabĕ de Angelis M; Roden M; Neschen S; Kastenmüller G; Wang-Sattler R
Diabetes; 2016 Dec; 65(12):3776-3785. PubMed ID: 27621107
[TBL] [Abstract][Full Text] [Related]
3. Lipoprotein risk factors for cardiovascular disease in patients with type 2 diabetes mellitus treated with oral antihyperglycaemic agents.
Chu JW; Abbasi F; McLaughlin TL; Lamendola C; Schaaf P; Carlson TH; Leary ET; Reaven GM
Diabetes Obes Metab; 2003 Sep; 5(5):333-7. PubMed ID: 12940871
[TBL] [Abstract][Full Text] [Related]
4. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
Lund SS; Tarnow L; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA
Eur J Endocrinol; 2008 Jan; 158(1):35-46. PubMed ID: 18166815
[TBL] [Abstract][Full Text] [Related]
5. Glucose and lipid effects of the ileal apical sodium-dependent bile acid transporter inhibitor GSK2330672: double-blind randomized trials with type 2 diabetes subjects taking metformin.
Nunez DJ; Yao X; Lin J; Walker A; Zuo P; Webster L; Krug-Gourley S; Zamek-Gliszczynski MJ; Gillmor DS; Johnson SL
Diabetes Obes Metab; 2016 Jul; 18(7):654-62. PubMed ID: 26939572
[TBL] [Abstract][Full Text] [Related]
6. Comparison of lipid profiles and lipoprotein a levels in patients with type 2 diabetes mellitus during oral hypoglycemic or insulin therapy.
Habib SS; Aslam M; Naveed AK; Razi MS
Saudi Med J; 2006 Feb; 27(2):174-80. PubMed ID: 16501671
[TBL] [Abstract][Full Text] [Related]
7. Comment on Xu et al. Effects of Metformin on Metabolite Profiles and LDL Cholesterol in Patients With Type 2 Diabetes. Diabetes Care 2015;38:1858-1867.
Sonne DP; Knop FK
Diabetes Care; 2015 Dec; 38(12):e215. PubMed ID: 26604291
[No Abstract] [Full Text] [Related]
8. Response to Comment on Xu et al. Effects of Metformin on Metabolite Profiles and LDL Cholesterol in Patients With Type 2 Diabetes. Diabetes Care 2015;38:1858-1867.
Brandmaier S; Xu T; Illig T; Suhre K; Adamski J; Wang-Sattler R
Diabetes Care; 2015 Dec; 38(12):e216-7. PubMed ID: 26604292
[No Abstract] [Full Text] [Related]
9. Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese subjects with mild glucose anomalies: a post-hoc analysis of the BIGPRO1 trial.
Fontbonne A; Diouf I; Baccara-Dinet M; Eschwege E; Charles MA
Diabetes Metab; 2009 Nov; 35(5):385-91. PubMed ID: 19665415
[TBL] [Abstract][Full Text] [Related]
10. [The effect of metformin on lipid parameters and on cardiovascular risk in patients with type 2 diabetes without statin therapy].
Kender Z; Groener JB; Reismann P; Kopf S
Orv Hetil; 2019 Aug; 160(34):1346-1352. PubMed ID: 31423831
[TBL] [Abstract][Full Text] [Related]
11. Metformin-induced changes in the gut microbiome and plasma metabolome are associated with cognition in men.
Rosell-Díaz M; Petit-Gay A; Molas-Prat C; Gallardo-Nuell L; Ramió-Torrentà L; Garre-Olmo J; Pérez-Brocal V; Moya A; Jové M; Pamplona R; Puig J; Ramos R; Bäckhed F; Mayneris-Perxachs J; Fernández-Real JM
Metabolism; 2024 Aug; 157():155941. PubMed ID: 38871078
[TBL] [Abstract][Full Text] [Related]
12. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review.
Wulffelé MG; Kooy A; de Zeeuw D; Stehouwer CD; Gansevoort RT
J Intern Med; 2004 Jul; 256(1):1-14. PubMed ID: 15189360
[TBL] [Abstract][Full Text] [Related]
13. Association between metformin use and below-the-knee arterial calcification score in type 2 diabetic patients.
Mary A; Hartemann A; Liabeuf S; Aubert CE; Kemel S; Salem JE; Cluzel P; Lenglet A; Massy ZA; Lalau JD; Mentaverri R; Bourron O; Kamel S
Cardiovasc Diabetol; 2017 Feb; 16(1):24. PubMed ID: 28202017
[TBL] [Abstract][Full Text] [Related]
14. PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia.
Pfützner A; Schöndorf T; Tschöpe D; Lobmann R; Merke J; Müller J; Lehmann U; Fuchs W; Forst T
Diabetes Technol Ther; 2011 Jun; 13(6):637-43. PubMed ID: 21457065
[TBL] [Abstract][Full Text] [Related]
15. Relationship between serum thyrotropin concentrations and metformin therapy in euthyroid patients with type 2 diabetes.
Díez JJ; Iglesias P
Clin Endocrinol (Oxf); 2013 Apr; 78(4):505-11. PubMed ID: 22686474
[TBL] [Abstract][Full Text] [Related]
16. [Primary preventive effect of metformin upon atherosclerosis in patients with type 2 diabetes mellitus].
Zhang XY; Du JL; Jia YJ; Bai R; Yang Y; Ba Y; Xing Q; Men LL
Zhonghua Yi Xue Za Zhi; 2009 Aug; 89(30):2134-7. PubMed ID: 20058619
[TBL] [Abstract][Full Text] [Related]
17. Untargeted serum metabolomics reveals Fu-Zhu-Jiang-Tang tablet and its optimal combination improve an impaired glucose and lipid metabolism in type II diabetic rats.
Tao Y; Chen X; Cai H; Li W; Cai B; Chai C; Di L; Shi L; Hu L
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Jan; 1040():222-232. PubMed ID: 27866845
[TBL] [Abstract][Full Text] [Related]
18. Effects of melatonin and zinc on lipid profile and renal function in type 2 diabetic patients poorly controlled with metformin.
Kadhim HM; Ismail SH; Hussein KI; Bakir IH; Sahib AS; Khalaf BH; Hussain SA
J Pineal Res; 2006 Sep; 41(2):189-93. PubMed ID: 16879326
[TBL] [Abstract][Full Text] [Related]
19. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes.
Betteridge DJ; Vergès B
Diabetologia; 2005 Dec; 48(12):2477-81. PubMed ID: 16283239
[TBL] [Abstract][Full Text] [Related]
20. Gliquidone versus metformin: differential effects on aorta in streptozotocin induced diabetic rats.
Tan Z; Xu Z; Gui Q; Wu W; Yang Y
Chin Med J (Engl); 2014; 127(7):1298-303. PubMed ID: 24709184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
